AR095208A1 - Pirrolotriazinas como inhibidores del canal del ión potasio - Google Patents

Pirrolotriazinas como inhibidores del canal del ión potasio

Info

Publication number
AR095208A1
AR095208A1 ARP140100817A ARP140100817A AR095208A1 AR 095208 A1 AR095208 A1 AR 095208A1 AR P140100817 A ARP140100817 A AR P140100817A AR P140100817 A ARP140100817 A AR P140100817A AR 095208 A1 AR095208 A1 AR 095208A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
substituted
independently selected
heteroaryl
Prior art date
Application number
ARP140100817A
Other languages
English (en)
Spanish (es)
Inventor
Srinivasu Pothukanuri
Kavitha Govindrajulu
Finlay Heather
Kumar Adisechan Ashok
Gunaga Prashantha
Lloyd John
Kumar Dhondi Naveen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR095208A1 publication Critical patent/AR095208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP140100817A 2013-03-11 2014-03-10 Pirrolotriazinas como inhibidores del canal del ión potasio AR095208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361775731P 2013-03-11 2013-03-11

Publications (1)

Publication Number Publication Date
AR095208A1 true AR095208A1 (es) 2015-09-30

Family

ID=51488539

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100817A AR095208A1 (es) 2013-03-11 2014-03-10 Pirrolotriazinas como inhibidores del canal del ión potasio

Country Status (8)

Country Link
US (1) US9050345B2 (OSRAM)
EP (1) EP2970296B1 (OSRAM)
JP (1) JP6427551B2 (OSRAM)
CN (1) CN105008367B (OSRAM)
AR (1) AR095208A1 (OSRAM)
TW (1) TW201444847A (OSRAM)
UY (1) UY35381A (OSRAM)
WO (1) WO2014143610A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2858987T1 (en) * 2012-06-11 2018-06-29 Bristol-Myers Squibb Company PREPARATION OF 5-PHENYL-4- (PYRIDIN-2-ILLETHYLAMINO) -CHUINAZOLIN-2-YL) -PIRIDIN-3-SULPHONAMIDE PHOSPHORAMIDIC ACID
EP2970294B1 (en) 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
EP2970199A1 (en) 2013-03-11 2016-01-20 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
JP6386527B2 (ja) 2013-03-11 2018-09-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのピロロピリダジン
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2018528951A (ja) * 2015-08-31 2018-10-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＴＧＦβ受容体アンタゴニスト
CN105111154A (zh) * 2015-09-15 2015-12-02 上海瑞博化学有限公司 一种5-氨基吡嗪-2-甲酸合成新工艺
US10221191B2 (en) 2015-12-22 2019-03-05 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EP3436461B1 (en) 2016-03-28 2023-11-01 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
KR102431405B1 (ko) * 2016-04-28 2022-08-10 다케다 야쿠힌 고교 가부시키가이샤 축합 헤테로시클릭 화합물
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
JP7675182B2 (ja) * 2020-11-10 2025-05-12 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
KR20250007533A (ko) 2022-04-08 2025-01-14 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, ras질환 및 섬유성 질환의 치료를 위한 ras 슈퍼패밀리 단백질과 상호작용하는 화합물
CN119677738A (zh) 2022-05-11 2025-03-21 福宏治疗公司 化合物及其用途
CN116063183B (zh) * 2023-01-28 2023-06-27 山东国邦药业有限公司 一种环丙胺的合成方法
WO2025077671A1 (zh) * 2023-10-09 2025-04-17 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
CN1149196C (zh) 1998-07-06 2004-05-12 布里斯托尔-迈尔斯斯奎布公司 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
KR100666514B1 (ko) * 1999-05-21 2007-02-28 브리스톨-마이어즈 스퀴브 컴페니 키나제의 피롤로트리아진 저해제
NZ525334A (en) * 2000-11-17 2005-07-29 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
US7034151B2 (en) 2003-02-05 2006-04-25 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine kinase inhibitors
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
EP1799218A1 (en) 2004-09-30 2007-06-27 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
AU2007223342A1 (en) 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
US20080064718A1 (en) 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
PL2041138T3 (pl) 2006-07-07 2014-11-28 Bristol Myers Squibb Co Pirolotriazyny jako inhibitory kinazy
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
JP5319659B2 (ja) 2007-04-18 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
AU2008289101A1 (en) * 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
CN102015719A (zh) 2008-03-06 2011-04-13 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
WO2010002472A1 (en) 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
JP5592890B2 (ja) * 2008-10-08 2014-09-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
ES2900504T3 (es) 2009-09-03 2022-03-17 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales iónicos de potasio
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
SI2858987T1 (en) * 2012-06-11 2018-06-29 Bristol-Myers Squibb Company PREPARATION OF 5-PHENYL-4- (PYRIDIN-2-ILLETHYLAMINO) -CHUINAZOLIN-2-YL) -PIRIDIN-3-SULPHONAMIDE PHOSPHORAMIDIC ACID

Also Published As

Publication number Publication date
WO2014143610A1 (en) 2014-09-18
EP2970296A1 (en) 2016-01-20
US9050345B2 (en) 2015-06-09
JP2016512505A (ja) 2016-04-28
CN105008367B (zh) 2017-08-29
JP6427551B2 (ja) 2018-11-21
US20140256719A1 (en) 2014-09-11
CN105008367A (zh) 2015-10-28
EP2970296B1 (en) 2016-12-21
TW201444847A (zh) 2014-12-01
UY35381A (es) 2014-09-30

Similar Documents

Publication Publication Date Title
AR095208A1 (es) Pirrolotriazinas como inhibidores del canal del ión potasio
AR093403A1 (es) COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
TR201902249T4 (tr) Trpa1 modülatörleri olarak faydalı ornatık heterosiklik sülfonamit bileşikleri.
CY1124537T1 (el) Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
AR094452A1 (es) COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa
AR094537A1 (es) COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
NZ732812A (en) Use of picolinamides and other compounds as fungicides
MX2017002328A (es) Analogos de dioxolano de uridina para el tratamiento del cancer.
AR077818A1 (es) Composiciones pesticidas
PE20151994A1 (es) Modificador del sabor dulce
AR099122A1 (es) Derivados de pirimidiniloxi benceno como herbicidas
PE20160126A1 (es) Derivados del bipirazol como inhibidores jak
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR092253A1 (es) Inhibidores de serina/treonina cinasa
PH12015502047A1 (en) Novel pyrimidine and pyridine compounds and their usage
MX380421B (es) Compuestos herbicidas de pirimidiniloxi benceno sustituido.
MX2015012111A (es) Moduladores de ship1 y métodos relacionados con éstos.
MX2015014406A (es) Carboxamidas fungicidas.
AR088320A1 (es) Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
AR097277A1 (es) Derivados de urea de piperidinas
AR099071A1 (es) Antagonistas selectivos de nr2b

Legal Events

Date Code Title Description
FB Suspension of granting procedure